Application of a TJP3 gene encoding protein in the preparation of ovarian cancer detection reagent
By studying the function of TJP3 gene encoding protein in ovarian cancer cells, the problem of lack of targeting and low sensitivity of diagnostic markers in the prior art was solved, and TJP3 was found to be a new biomarker and therapeutic target. , improves the diagnosis and treatment effect of ovarian cancer.
Patent Information
- Application Number
- CN202210166408.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-02-23
AI Technical Summary
Existing ovarian cancer treatment drugs lack targeting, low sensitivity and specificity of diagnostic markers, and poor stability of tumor markers serum levels, making it difficult to achieve accurate early diagnosis and effective treatment.
By studying the expression and function of TJP3 gene encoding protein in ovarian cancer cells, a TJP3 overexpression and knockdown cell model was constructed, and its effects on the proliferation, migration, invasion and apoptosis of ovarian cancer cells were detected, and its role as a new organism Markers and therapeutic targets.
The important role of TJP3 in the proliferation, migration and apoptosis of ovarian cancer cells is clarified, new biomarkers and potential therapeutic basis are provided, and the diagnosis and treatment effect of ovarian cancer is improved.
Smart Images

Figure CN114487419B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to an application of a TJP3 gene encoding protein in the preparation of an ovarian cancer detection reagent. Background Art
[0002] At present, ovarian cancer is one of the three major malignant tumors of the female reproductive system. Its high mortality rate and low cure rate are a major problem in the treatment of ovarian cancer. Since there are often no clinical symptoms in the early stages and it is often discovered in the late stages, a large number of patients cannot receive timely treatment. In addition, most of the existing therapeutic drugs lack targeting, which often leads to poor treatment effects. Therefore, in-depth exploration of the occurrence and development mechanism of ovarian cancer and the search for new targets for effective intervention can provide a basis and guidance for the early diagnosis and treatment of ovarian cancer.
[0003] Although it is known that the occurrence and development of ovarian cancer involves the activation of oncogenes and the inactivation of tumor suppressor genes, and that the activation of oncogenes and the inactivation of tumor suppressor genes make ovarian cancer cells more likely to escape the effects of the immune system or anticancer drugs, in clinical practice, the role of existing molecular markers in evaluating the occurrence, development, and prognosis of ovarian cancer is still very limited. Therefore, in-depth research on the influencing factors and related mechanisms of the malignant biological behavior of ovarian cancer and the search for new key genes and regulatory pathways in the occurrence and development of ovarian cancer are very important for improving treatment efficacy and prognosis.
[0004] Tight junction proteins (TJPs) are the first confirmed attachment proteins of tight junctions. They belong to the MAGUKs family and contain three isoforms, namely TJP1, TJP2 and TJP3. Studies have shown that TJP1 and TJP2 are essential for the assembly of tight junction components and the permeability of the structure, respectively. In the absence of TJP1 and TJP2, cells cannot form TJs. TJP1 and TJP2 are expressed in both epithelia and endothelia, while TJP3 is only expressed in epithelia. Despite a series of studies on TJPs, their functions in vivo, especially the in vivo function of TJP3, are still fragmentary. It has been reported that a TJP3 knockout mouse model was constructed. Short-term observation of the survival of mice was not significantly affected, and they were fertile. Strict phenotypic analysis did not find obvious abnormalities, indicating that the role of TJP3 in normal mice is not as obvious as TJP1 and TJP2, and it is non-lethal. However, due to its particularity in tissue localization, it is still worth studying.
[0005] With the gradual completion of the Human Genome Project, gene research has progressed to the stage of functional genomics. This project aims to study gene function, genome expression regulation and the function of protein products. Gene function is realized in multi-level complex organisms composed of cells, so building a cell model to study gene function is the basic idea. At present, the study of the function of gene-encoded protein products at the cellular level usually uses gene editing technology to knock down or overexpress the target gene, detect changes in cell behavior such as proliferation, apoptosis, migration, invasion, or changes in cell sensitivity to drugs, hypoxia tolerance, etc., so as to determine the function and role of the gene in the cell or organism.
[0006] The transcriptome sequencing analysis of tumor and normal ovarian tissues of 31 patients with epithelial ovarian cancer was performed using the next-generation sequencing (NGS) method, and the differentially expressed gene TJP3 was found. On this basis, molecular biological experiments were used to further verify the expression of TJP3 at the mRNA and protein levels in normal ovarian epithelial cell lines and epithelial ovarian cancer cell lines to support the reliability of the previous high-throughput data. TJP3 overexpression and knockdown ovarian cancer cell models were constructed, and through a series of cell proliferation activity, cell apoptosis, cell migration, and cell invasion experiments, it was clarified that high expression of TJP3 promoted the proliferation activity, cell migration, and cell invasion of ovarian cancer cells, and inhibited cell apoptosis.
[0007] Currently, common tumor markers used in clinical practice for early detection of ovarian cancer include CA125 and human epididymis protein (HE4).
[0008] CA125 was first discovered by Bast in epithelial ovarian cancer. It is one of the most widely studied serum tumor markers and the most commonly used indicator for the diagnosis of ovarian epithelial tumors. The content in the serum of healthy people is very low. At present, serum CA125 levels >35U / ml are often used clinically as the critical value for judging malignant ovarian tumors. In the vast majority of epithelial ovarian cancers, the content of CA125 in serum can be detected to be elevated. However, its sensitivity to early ovarian cancer is low, and only 30% of patients with stage I ovarian cancer have elevated levels. Moreover, elevated CA125 can also be detected in other female inflammatory diseases, such as ovarian chocolate cysts, follicular cysts, pregnancy and menstruation, which affects the accurate diagnosis of ovarian cancer. The specificity and sensitivity of its detection are not ideal.
[0009] HE4 is an acidic inhibitory protein, which is mainly expressed and secreted in the reproductive epithelium of normal women, and is not expressed in normal ovarian tissue. Therefore, HE4 is almost undetectable in normal humans, but HE4 is highly expressed in OC patients, and has differential expression characteristics in different types of OC patients, with 100% expression in endometrioid ovarian cancer, 93% expression in serous ovarian cancer, and only 50% expression in clear cell ovarian cancer. Existing clinical studies have shown that the sensitivity of HE4 in detecting ovarian cancer is lower than that of CA125, but its specificity is significantly higher than that of CA125. Therefore, the two indicators are often combined clinically as screening indicators for early diagnosis of ovarian cancer.
[0010] At present, various tumor markers used in clinical practice have their own advantages and disadvantages. Through the combined use of multiple tumor markers, the accuracy of OC diagnosis has been gradually improved and the sensitivity of early diagnosis has been improved to a certain extent. However, the application of existing tumor markers also reflects their limitations. For example, some normal cells also produce tumor markers, and diseases other than cancer or stress states may also cause tumor marker levels to rise significantly; the serum level of tumor markers is not stable and can change over time, making it difficult to obtain consistent results; some tumors do not produce tumor markers that can be detected in the blood.
[0011] Through the above analysis, the problems and defects of the prior art are as follows:
[0012] (1) Most of the existing ovarian cancer treatment drugs lack targeting, resulting in poor therapeutic effects; at the same time, the role of existing molecular markers in evaluating the occurrence, development and prognosis of ovarian cancer is very limited.
[0013] (2) The existing tumor marker CA125 has low specificity and sensitivity for early ovarian cancer. At the same time, the sensitivity of human epididymal protein HE4 in detecting ovarian cancer is lower than that of CA125.
[0014] (3) Existing tumor markers also have limitations in their application. For example, some normal cells also produce tumor markers, and diseases other than cancer or stress conditions may also cause tumor marker levels to rise significantly. The serum levels of tumor markers are not stable and may change over time, making it difficult to obtain consistent results. Some tumors do not produce tumor markers that can be detected in the blood.
[0015] The difficulty of solving the above problems and defects is:
[0016] Since there is no safe and effective commercial detection method, the prevention and control of ovarian cancer mainly relies on regular health examinations and routine cancer gene marker detection. The difficulty in the development of early prevention and treatment of ovarian cancer and detection kits lies in the fact that the research on the pathogenesis of ovarian cancer itself is not comprehensive.
[0017] The biological characteristics of cells are complex, and there are many oncogenes and tumor suppressor genes that regulate their occurrence and development, and the mechanism research is very limited; the genome involved is huge, the functions of more than half of the genes are unknown, and the functional research of known genes is also very weak.
[0018] The significance of solving the above problems and defects is:
[0019] More and more studies have shown that tumors are essentially gene-related diseases, and many genes are involved in the development of ovarian cancer. Therefore, studying the functions of genes related to the malignant biology of ovarian cancer cells is of great significance for exploring the occurrence of ovarian cancer, controlling the proliferation of tumor cells, and improving the accuracy of early diagnosis of ovarian cancer. Summary of the invention
[0020] In view of the problems existing in the prior art, the present invention provides an application of a protein encoded by a TJP3 gene in the preparation of an ovarian cancer detection reagent.
[0021] The present invention is achieved by using a protein encoded by a TJP3 gene in the preparation of an ovarian cancer detection preparation.
[0022] Another object of the present invention is to provide an ovarian cancer detection kit, comprising a protein encoded by the TJP3 gene.
[0023] Another object of the present invention is to provide a method for determining the function of an encoded protein, comprising the following steps:
[0024] Step 1, detecting the expression level of TJP3 in normal ovarian epithelial cells and epithelial ovarian cancer cell lines;
[0025] Step 2: Construction of knockdown and overexpression stable cell lines;
[0026] Step 3, detecting the effect of TJP3 on the proliferation activity of ovarian cancer Caov-3 cells;
[0027] Step 4: Detect the effect of TJP3 on the migration and invasion of ovarian cancer Caov-3 cells;
[0028] Step 5, detecting the effect of TJP3 on the expression of EMT-related proteins in ovarian cancer Caov-3 cells;
[0029] Step six, detect the effect of TJP3 on apoptosis of ovarian cancer Caov-3 cells.
[0030] Furthermore, the method for detecting the expression level of TJP3 in normal ovarian epithelial cells and epithelial ovarian cancer cell lines in step 1 includes:
[0031] One normal ovarian epithelial cell line, four epithelial ovarian cancer cell lines and one fibroblastic ovarian cancer cell line were selected to detect the expression level of TJP3.
[0032] Furthermore, the method for constructing knockdown and overexpression stable cell lines in step 2 includes:
[0033] The knockdown vectors GV248, GV248-TJP3 and the overexpression vectors GV365, GV365-TJP3 were transferred into Caov-3 cells, forming two experimental groups together with wild-type cells. The transfected cells were screened with puromycin selection pressure for 3 weeks, and the mRNA and protein levels were used to verify whether the obtained stable cell lines stably expressed TJP3, and then the effects of TJP3 on a series of biological functions related to the occurrence and development of tumors, such as Caov-3 cell proliferation and cell apoptosis, were analyzed.
[0034] Furthermore, the experimental groups include NC, Ctrl-si, TJP3-si knockdown experimental groups and NC, Ctrl-EO, TJP3-EO overexpression experimental groups.
[0035] Furthermore, the method for detecting the effect of TJP3 on the proliferation activity of ovarian cancer Caov-3 cells in step three includes: detecting cell activity using the MTT method to analyze whether TJP3 has an effect on the proliferation of Caov-3 cells.
[0036] Furthermore, the method for detecting the effect of TJP3 on the migration and invasion of ovarian cancer Caov-3 cells in step 4 includes: using a cell scratch assay and a transwell chamber invasion assay to analyze the effects of TJP3 knockdown and overexpression on the migration and invasion ability of Caov-3 cells.
[0037] Furthermore, the method for detecting the effect of TJP3 on the expression of EMT-related proteins in ovarian cancer Caov-3 cells in step five includes: using Western Blot to detect the effect of TJP3 on the expression of EMT-related proteins in ovarian cancer Caov-3 cells.
[0038] Furthermore, the method for detecting the effect of TJP3 on apoptosis of ovarian cancer Caov-3 cells in step six includes: using Annexin V-FITC / PI double staining cell apoptosis detection method to detect the effect of TJP3 on cell apoptosis.
[0039] In combination with all the above technical solutions, the advantages and positive effects of the present invention are as follows: Up to now, there are few literature reports on TJP3 in the field of gynecological tumors, and there are no reports related to ovarian cancer. The present invention verifies its role in the occurrence and development of ovarian cancer through analysis, and can lay a good foundation for further in-depth exploration of TJP3 in the clinical diagnosis, typing, treatment, prognosis and other aspects of ovarian cancer.
[0040] The experimental results of the present invention show that TJP3 is highly expressed in ovarian cancer patients, plays an important role in the proliferation, apoptosis and EMT of ovarian cancer cells, and can become a potential new biomarker for ovarian cancer.
[0041] The present invention is expected to provide new and valuable basis and reference for the diagnosis and treatment of ovarian cancer.
[0042] The experimental results of the present invention clearly show that high expression of TJP3 promotes the proliferation activity, cell migration, cell invasion and inhibits the biological function of cell apoptosis in ovarian cancer cells, indicating that TJP3 has a clear biological function in the occurrence and development of ovarian cancer cells.
[0043] The existing tumor markers reflect many limitations in their application, for example, some normal cells also produce tumor markers, and diseases other than cancer or stress states may also significantly increase the levels of tumor markers; the serum levels of tumor markers are not stable and may change over time, making it difficult to obtain consistent results; some tumors do not produce tumor markers that can be detected in the blood. The next-generation sequencing technology provides new technical means for studying gene function and also provides reliable clues for finding candidate target molecules and biomarkers for tumors. The TJP3 functional study covers the detection data of clinical tissue samples and the verification of in vitro cell levels. The experimental data is reliable and the result analysis is reasonable. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments of the present invention. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0045] Figure 1 The present invention provides a flowchart of a method for determining the function of an encoded protein.
[0046] Figure 2A to Figure 2C The mRNA expression of TJP3 in normal ovarian epithelial and ovarian cancer cell lines provided by the embodiment of the present invention is
[0047] and protein expression schematic.
[0048] Figure 3A to Figure 3C It is a schematic diagram of the expression of TJP3 mRNA and protein in the knockdown and overexpression groups of Caov-3 cell lines provided in the embodiments of the present invention.
[0049] Figure 4A to Figure 4B The MTT method provided in the embodiment of the present invention is used to detect TJP3 knockdown and overexpression group Caov-3 cells
[0050] Schematic diagram of the in vitro proliferation ability.
[0051] Figure 5A to Figure 5D Schematic diagram of the effects of TJP3 knockdown and overexpression on the migration and invasion ability of Caov-3 cells provided in the embodiments of the present invention.
[0052] Figure 5A to Figure 5B It is a schematic diagram of the cell scratch test results provided in the embodiment of the present invention.
[0053] Figure 5C to Figure 5D It is a schematic diagram of the results of the Transwell chamber invasion experiment provided in an embodiment of the present invention.
[0054] Figure 6A to Figure 6B Schematic diagram of the effects of TJP3 knockdown and overexpression on the expression of EMT-related proteins in Caov-3 cells provided in an embodiment of the present invention.
[0055] Figure 7A to Figure 7B It is a schematic diagram of the effect of TJP3 on Caov-3 cell apoptosis detected by Annexin V-FITC / PI double staining of cell apoptosis provided in an embodiment of the present invention. DETAILED DESCRIPTION
[0056] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the following embodiments are described.
[0057] The present invention will be described in further detail. It should be understood that the specific embodiments described herein are only for
[0058] It is intended to explain the present invention, not to limit the present invention.
[0059] In view of the problems existing in the prior art, the present invention provides an application of a protein encoded by a TJP3 gene in the preparation of an ovarian cancer detection reagent. The present invention is described in detail below in conjunction with the accompanying drawings.
[0060] The present invention provides an application of a TJP3 gene encoding protein in the preparation of an ovarian cancer detection preparation.
[0061] Another object of the present invention is to provide an ovarian cancer detection kit, comprising a protein encoded by the TJP3 gene
[0062] like Figure 1As shown, the method for determining the function of the encoded protein provided in the embodiment of the present invention comprises the following steps:
[0063] S101, detection of the expression level of TJP3 in normal ovarian epithelial cells and epithelial ovarian cancer cell lines;
[0064] S102, construction of knockdown and overexpression stable cell lines;
[0065] S103, to detect the effect of TJP3 on the proliferation activity of ovarian cancer Caov-3 cells;
[0066] S104, to detect the effect of TJP3 on the migration and invasion of ovarian cancer Caov-3 cells;
[0067] S105, to detect the effect of TJP3 on the expression of EMT-related proteins in ovarian cancer Caov-3 cells;
[0068] S106, detect the effect of TJP3 on apoptosis of ovarian cancer Caov-3 cells.
[0069] The technical solution of the present invention is further described below in conjunction with specific embodiments.
[0070] Example: Biological role of TJP3 gene-encoded protein in the development of ovarian cancer
[0071] 1 Experimental Materials
[0072] 1.1 Cell lines
[0073]
[0074] 1.2TJP3-Si and JPS3-OE and carrier information
[0075] 1) According to the human TJP3 mRNA sequence in the Gene Bank database (NM_001267560.2), three TJP3 sh-RNA sequences were designed using the Sigma online Predesigned siRNA designer. The sequence information is shown in the table below:
[0076] The three TJP3 sh-RNA sequences include: TJP3-shRNA-1, TJP3-shRNA-2, and TJP3-shRNA-3;
[0077] The sequence of TJP3-shRNA-1 is SEQ ID NO: 1: ggtgaacattcctcgagga;
[0078] The sequence of TJP3-shRNA-2 is SEQ ID NO: 2: gcagaagttctcgagaac;
[0079] The sequence of TJP3-shRNA-3 is SEQ ID NO: 3: gctactcgagtagcttccct.
[0080] The sequence of TJP3-control is SEQ ID NO: 4: ttctccgaacgtgtcacgt.
[0081] The details are as follows:
[0082] NO. Accession Target Seq GC% TJP3-shRNA-1 NM_001267560.2 ggtgaacattcctcgagga 52.6% TJP3-shRNA-2 NM_001267560.2 gcagaagttctcgagaac 50% TJP3-shRNA-3 NM_001267560.2 gctactcgagtagcttccct 55% TJP3-control ttctccgaacgtgtcacgt
[0083] 2) The overexpressed sequence was synthesized using a reverse transcribed cDNA template.
[0084] 3) The sequence information is submitted to GeneCare for synthesis of lentiviral knockdown and overexpression vectors.
[0085] The knockdown vector GV248, the element sequence is: hU6-MCS-Ubiquitin-EGFP-IRES-puromycin.
[0086] Overexpression vector GV365, the order of elements is: Ubi-MCS-3FLAG-CMV-EGFP;
[0087] 2 Experimental methods
[0088] 2.1 Cell culture
[0089] The cells used in the experiment were cultured in DMEM or 1640 medium containing 10% newborn calf serum, 100 μg / mL streptomycin and 100 U / mL penicillin, and cultured in a 37°C, 5% CO2 incubator.
[0090] (1) Cell recovery
[0091] Place 8 mL of DMEM medium containing 10% fetal bovine serum in a 10 mL centrifuge tube for later use. Take out the cells to be revived from liquid nitrogen and place them in a 42°C constant temperature water bath to quickly thaw (completed within 1 minute). Transfer the thawed cells into a centrifuge tube containing culture medium, centrifuge at 800 rpm for 5 minutes, and discard the supernatant. Add 2 mL of DMEM cell culture medium containing 20% fetal bovine serum, resuspend the cells, and culture in a 37°C, 5% CO2 incubator. After the cells are completely attached (about 24 hours), replace with DMEM medium containing 10% fetal bovine serum.
[0092] (2) Cell passaging
[0093] Discard the culture medium in the cell culture flask, wash the cell surface with D-Hanks 1-2 times, add about 1mL of 0.25% trypsin, observe while digesting, and when the cell morphology changes, quickly discard the trypsin, add 2mL of DMEM medium containing 10% fetal bovine serum, blow off the adherent cells with a pipette, and place the cells in a 37℃, 5% CO2 incubator to pass the cells at an appropriate cell density.
[0094] (3) Cell cryopreservation
[0095] The culture medium of the cultured cells that grew well after recovery was discarded, and the cell surface was rinsed with D-Hanks
[0096] After 1-2 times of culture medium, add 0.25% trypsin to digest the cells, observe the cell morphology under the microscope, and after the cell morphology changes, discard the cell digestion solution and terminate the digestion with a small amount of DMEM culture medium containing 10% fetal bovine serum. Centrifuge at 800rpm for 5 minutes and discard the supernatant. Add about 1mL of freezing solution, blow to resuspend the cells, transfer to a freezing tube, place at 4℃ for 15min, -20℃ for 30min, and finally put it in a freezer box in a -80℃ refrigerator. Take it out of the freezer box the next day and place it in liquid nitrogen.
[0097] 2.2 Cell transfection
[0098] 2.2.1 Calcium phosphate transfection method
[0099] The cells were transfected according to the instructions of the Biotech calcium phosphate cell transfection kit.
[0100] 1) 24 h before transfection, cells were cultured at 1×10 5 The cells were seeded at a density of 100 μg / well in a 24-well plate, so that the cell density reached about 70% on the next day.
[0101] 2) Take 0.5-1.5 μg of the plasmid DNA to be transfected and add it to 25 μL of calcium chloride solution and mix thoroughly.
[0102] 3) Slowly add the DNA-calcium chloride mixture into 25 μL BBS solution, mix thoroughly by pipetting, and incubate at room temperature for 20-30 minutes.
[0103] 4) Evenly drop 50 μL of DAN-calcium chloride-BBS mixture into a 24-well plate, continue to culture in the cell incubator for 4-6 hours, discard the culture medium containing the transfection reagent, add 2 mL of fresh DMEM medium containing 10% fetal bovine serum, continue to culture for 48 hours before performing relevant tests.
[0104] 2.2.2. Lentiviral transfection
[0105] The cells were transfected according to the instructions of the GeneCare lentiviral transfection kit.
[0106] 1) 18-24 hours before transfection, ovarian cancer cells were seeded into 24-well plates at 1×10 5 cells / well, so that the cell density reached about 70% during lentiviral transfection.
[0107] 2) While ensuring that the cells are adherent and in good condition, replace the original culture medium with 2 ml of fresh culture medium containing 6 μg / ml polybrene, add 1×108 U of virus suspension and incubate at 37°C.
[0108] 3) After 6-12 hours, replace the virus-containing medium with fresh medium.
[0109] 4) After continuing to culture for 48 hours, relevant treatment or testing can be carried out.
[0110] 2.2.3. Establishment of stable transfected cell lines
[0111] 1) The cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C and 5% CO2.
[0112] 2) 24 h before transfection, cells were cultured at 5×10 5 The cells were inoculated at a density of 1.5 × 10 / well in a 6-well plate, and 2 mL of DMEM medium containing 10% fetal bovine serum was added to each well. The cell density reached about 70% during transfection.
[0113] 3) According to the instructions of the GeneCare lentiviral transfection kit, Ctrol-si, TJP3-si, Ctrol-OE, and TJP3-OE were respectively transferred into the cells. 48 hours after transfection, 2 μg / ml puromycin / pressure screening was used for about 3 weeks to obtain the corresponding stable transfected cell lines.
[0114] 2.3 Total RNA extraction from cells
[0115] 1) Collect cells by centrifugation.
[0116] 2) Disrupt the cells by adding 0.75 mL of Trizol reagent to every 0.25 mL of sample and lyse them by pipetting.
[0117] 3) Centrifuge at 4-10°C, 12,000×g for 5 min, collect the clarified supernatant into a new centrifuge tube, and incubate for 5 min to completely dissociate the nucleoprotein complex.
[0118] 4) Add 0.2 mL of chloroform per 1 mL of Trizol reagent and incubate for 2–3 minutes.
[0119] 5) Centrifuge at 4°C, 12,000 × g for 15 min. After centrifugation, the mixture is divided into three layers: the lower layer is a red phenol-chloroform layer, the middle layer is an organic phase containing protein and other impurities, and the upper layer is a colorless aqueous phase (containing RNA).
[0120] 6) Transfer the aqueous phase containing RNA to a new centrifuge tube.
[0121] 7) Precipitate RNA: a. Add 5-10 μg of RNase-free glycogen as a carrier to the aqueous phase to co-precipitate RNA and glycogen; b. Add 0.5 mL of isopropanol for every 1 mL of Trizol; c. Incubate for 10 min; d. Centrifuge at 4°C, 12,000 × g for 15 min. The total RNA will precipitate at the bottom of the centrifuge tube as a white gel-like precipitate. Discard the supernatant.
[0122] 8) Clean RNA: a. Add 1 mL of 75% ethanol for every 1 mL of Trizol used; b. Vortex the sample briefly, then centrifuge at 7500×g for 5 min at 4°C and discard the supernatant; c. Vacuum or air-dry the RNA pellet for 5-10 min;
[0123] 9) Dissolve RNA: Add 20-50 μL RNase free water to the RNA precipitate and gently pipette to dissolve; place in a 55-60℃ water bath or heating module and incubate for 10-15 minutes to accelerate dissolution.
[0124] 2.4 RNA quality testing
[0125] RNA quality was determined spectrophotometrically, total RNA content was determined by absorbance at 260 nm, and RNA purity was determined by absorbance at 280 nm.
[0126] Determination and calculation: Dilute the RNA to be tested with RNase free water, and measure the absorbance at 260nm and 280nm respectively; use the formula (A260×dilution×40=Xμg RNA / mL) to calculate the RNA concentration;
[0127] 260 / A280≈2, the RNA quality is high.
[0128] 1.0% agarose gel electrophoresis was used to observe whether RNA was degraded or contaminated.
[0129] 2.5 Reverse transcription and cDNA synthesis
[0130] Utilizing SuperScript TM III RT / Platinum TM The specific steps of the experiment are as follows.
[0131] 1) Add the reagents to the PCR tube in the following order (total system 25 μl):
[0132] Reagents Volume (μl) 2×Reaction Mix 12.5 Total RNA 1 Sense primer 1 Anti-sense primer 1 <![CDATA[SuperScript TM III RT / Platinum TM Taq Mix]]> 1 DEPC water 8.5
[0133] 2) Gently mix all reagents.
[0134] 3) Set the reaction program:
[0135]
[0136] 4) On-machine reaction.
[0137] 2.6 PCR reaction
[0138] 1) PCR reaction primers:
[0139] According to the TJP3 sequence in the Genebank database, specific primers were designed using Primer Premier 6. The primer sequences are as follows:
[0140] The TJP3 primer is shown in SEQ ID NO: 5:
[0141] TJP3-upstream primer: 5'-aaactggcttctcgcaacac-3'
[0142] TJP3-downstream primer: 5'-ccttctacatccgcactcact-3'
[0143] GAPDH was used as an internal reference, and the primer sequences were as follows:
[0144] The GAPDH primer is shown in SEQ ID NO: 6:
[0145] GAPDH-upstream primer: 5'-gacctgacctgccgtctag-3'
[0146] GAPDH-downstream primer: 5'-gacctgacctgccgtctag-3'
[0147] The primers were synthesized by BGI.
[0148] 2) Add reagents to a 200 μl PCR tube in sequence according to the following reaction system;
[0149]
[0150] 3) Pre-denaturation at 95°C for 5 min, denaturation at 94°C for 30 s, annealing and extension at 60°C for 1 min, for a total of 40 cycles, the melting curve temperature was set at 60°C-95°C, the reaction conditions were set, and the detection was performed in an ABI7500 real-time fluorescence quantitative PCR instrument.
[0151] 2.7 Total protein extraction
[0152] 1) The cells of each experimental group were inoculated into a 6-well plate. When the cell density reached 90%, the culture medium was aspirated, the cells were washed twice with PBS, and the cells were collected by trypsin digestion.
[0153] 2) Centrifuge at 5000 rpm for 5 min and discard the supernatant.
[0154] 3) Add an appropriate amount of RIPA lysis buffer to the precipitate and place it in an ice box. Vortex vigorously for 20 seconds every 5 minutes for 30 minutes.
[0155] 4) Centrifuge at 12,000 rpm for 10 min.
[0156] 5) Collect the supernatant into a new centrifuge tube.
[0157] 6) Prepare for quantitative testing.
[0158] 2.8 BCA protein quantitative detection
[0159] 1) Standard curve drawing: Take an ELISA plate and add reagents according to Table 1:
[0160] Table 1 Standard curve drawing and sample addition table
[0161] Hole No. 0 1 2 3 4 5 6 7 Protein solution (μl) 0 1 2 4 8 12 1 6 20 Deionized water (μl) 20 19 18 16 1 2 8 4 0 Protein content (μg) 0 0.5 1 2 4 6 8 10
[0162] 2) Prepare BCA working solution according to the number of samples.
[0163] 3) Add 200 μl of BCA working solution to each well and mix thoroughly.
[0164] 4) Place the ELISA plate at 37°C for 30 min.
[0165] 5) Cool to room temperature and measure the absorbance at a wavelength of 562 nm.
[0166] 6) Calculate the corresponding protein content (μg) and concentration based on the absorbance value of the measured sample and the drawn standard curve.
[0167] 2.9SDS-PAGE and Western Blot
[0168] 1) Preparation of relevant reagents
[0169] (a) Acrylamide stock solution: acrylamide / methylenebisacrylamide (29.1 g / 0.9 g); separation gel buffer: 1.5 M Tris-HCl, pH 8.8; stacking gel buffer: 0.5 M Tris-HCl, pH 6.8; 10% (w / v) SDS; 10% (w / v) ammonium persulfate solution; polymerization agent TEMED.
[0170] (b) Preparation of 10× transfer buffer (500 mL)
[0171] Tris (25mmol / L) 1 5.15g Glycine (192mmol / L) 72.1g Sterile water Make up to 500mL
[0172] When using 20% methanol, add it in proportion
[0173] (c) Preparation of 10× electrophoresis buffer
[0174] Tris (25mmol / L) 1 5.18g Glycine (250mmol / L) 94g SDS (0.1%) 5g
[0175] (d) 20×TBST (pH 7.6, 500 mL)
[0176] Tris 24.2g NaCl 80g 1 M HCl Adjust pH to 7.6 Sterile water Make up to 500mL
[0177] When using, add Tween 20 at a ratio of 1×TBS / Tween 20=1000 / 1.
[0178] (e) Blocking solution: Prepare 5% skim milk powder in TBST.
[0179] 2) Preparation of SDS-PAGE gel
[0180] ① Separation gel (10%): double distilled water 3.3 ml, 1.5 M Tris 2.7 ml, 30% Acr / Bis 2 ml, 10% SDS 0.09 ml, 10% Aps 0.06 ml, TEMED 6 μL; total volume 8.156 ml.
[0181] ② Concentrating gel (5%): double distilled water 2.3 ml, 1.0 M Tris 1 ml, 30% Acr / Bis 0.67 ml, 10% SDS 0.04 ml, 10% Aps 0.02 ml, TEMED 8 μL; total volume 40.038 ml.
[0182] 3) SDS-PAGE electrophoresis
[0183] ① Prepare protein loading buffer and heat at 95℃ for 5min;
[0184] ② Add 1× electrophoresis buffer to the electrophoresis tank;
[0185] ③Electrophoresis: 80V constant voltage electrophoresis until bromophenol blue comes out of the bottom of the gel.
[0186] 4) Protein transfer
[0187] ① PVDF membrane methanol pretreatment;
[0188] ② Make a gel transfer stacking layer and remove bubbles;
[0189] ③ Place the transfer clip in the direction of positive and negative poles;
[0190] ④100V constant voltage for 2h;
[0191] 5) Immunoblotting
[0192] ① Take out the hybridization membrane and rinse it 3 times, 5 minutes each time;
[0193] ② Block with 5% skim milk powder blocking solution at room temperature for 1 hour;
[0194] ③ According to the optimal color development conditions of the pre-experiment, add the blocking solution containing the primary antibody and incubate overnight at 4°C;
[0195] ④Wash the membrane with TBST, add secondary antibody dilution solution and incubate at room temperature for 1 hour;
[0196] ⑤Wash the membrane with TBST;
[0197] ⑥ Temporarily prepare chemiluminescent substrate, evenly drop it onto the membrane surface, and react for 5 minutes in the dark;
[0198] ⑦ Place the membrane into the dark box of the gel imaging system for imaging;
[0199] ⑧Record the experimental results.
[0200] 2.10 MTT assay for cell viability
[0201] 1) Reagents
[0202] The concentration of MTT is 5 mg / mL. Weigh 0.5 g of MTT, dissolve it in 100 mL of phosphate buffered saline (PBS) or culture medium without phenol red, and store it at 4°C away from light. During the preparation and storage process, wrap the container with tin foil to avoid light.
[0203] 2) Experimental procedures
[0204] ① Each group of stably transfected cells was digested with 0.25% trypsin to prepare a single cell suspension, counted, and inoculated into a 96-well culture plate, with 200 μL in each well (2×103 cells per well), and 3 replicate wells were set for each group of stably transfected cells, and a total of 7 96-well flat-bottom plates were inoculated (the edge wells were filled with sterile PBS). At the same time, a zero well (blank culture medium) was set.
[0205] ② Place in an incubator at 37°C with 5% CO2 and observe under an inverted microscope. After the cells adhere to the wall, continue to incubate for 72 hours and detect once every 12 hours, for a total of 6 times.
[0206] ③ Add 20 μL of 5 mg / mL MTT to each well and continue incubation at 37°C for 4 h.
[0207] ④Terminate the culture and carefully remove the culture medium in the wells.
[0208] ⑤ Add 100 μL of dimethyl sulfoxide to each well and shake on a shaker for 10 minutes.
[0209] ⑥ Use enzyme-linked immunosorbent assay to detect its OD value at a wavelength of 570nm.
[0210] 2.11 Scratch assay to detect migration ability of ovarian cancer cells
[0211] 1) Digest each group of cells with 0.25% trypsin, count and plate at 5×105 cells / well in a 6-well plate, with 3 replicate wells for each group of cells.
[0212] 2) Culture in an incubator at 37°C with 5% CO2 overnight until the cell density reaches about 80%.
[0213] 3) Use the yellow pipette tip to scratch the cell culture plate with a width of about 5 mm. The pipette tip should be perpendicular to the cell plane and not tilted.
[0214] 4) Wash with PBS three times to fully remove the detached cells.
[0215] 5) Add fresh culture medium and continue to culture the cells. After 24 hours of culture, observe and take pictures.
[0216] 2.12 Transwell assay to detect ovarian cancer cell invasion ability
[0217] 1) Transwell chamber preparation
[0218] ① Thaw Matrigel overnight at 4°C and dilute Matrigel 1:3 with pre-cooled serum-free DMEM medium to a final concentration of 1 mg / mL.
[0219] ② Place the transwell chamber on a 24-well plate and add 100 μL of diluted Matrigel. Incubate at 37°C for 4 h to allow the gel to completely solidify.
[0220] 2) Inoculation of cell suspension
[0221] Prepare cell suspension with DMEM medium containing 10% fetal bovine serum, count, add 5×104 cells / well, and add 600 μL normal DMEM to culture the lower chamber based on the transwell.
[0222] 3) Place the cell culture plate in a cell incubator at 37°C containing 5% CO2 and culture for 40 hours.
[0223] 4) Remove the transwell chamber from the 24-well cell plate and wash with PBS three times, 3-5 minutes each time.
[0224] 5) Fix the cells with 4% paraformaldehyde for 30 min and wash with PBS three times, each time for 3-5 min.
[0225] 6) Carefully remove the cells that failed to invade the transwell chamber using a cotton swab.
[0226] 7) Permeabilize with 0.5% TritonX-100 for 5 min and wash with PBS three times, each time for 3-5 min.
[0227] 8) Stain the cell nucleus with hematoxylin for 10 min and rinse with water.
[0228] 9) Observe and take photos under a microscope.
[0229] 10) Result Statistics
[0230] 2.13 Annexin V-FITC / PI double staining for cell apoptosis detection
[0231] After culturing the cells in each group in complete medium for 96 hours, the apoptosis of cells was detected by flow cytometry according to the instructions of Annexin V-FITC / PI kit:
[0232] 1) Centrifuge each reagent before opening it to collect the liquid on the tube wall and tube mouth to avoid loss.
[0233] 2) Dilute 4X Binding Buffer to 1X Binding Buffer with distilled water.
[0234] 3) Wash the collected cells gently with PBS and shake gently.
[0235] 4) Resuspend the cells in 195 μl of 1X Binding Buffer to a cell density of 2 to 5 × 10 5 cells / ml.
[0236] 5) Add 5 μl of Annexin V-FITC and PI to 190 μl of cell resuspension, respectively, protect from light, mix well, and incubate at room temperature for 10 to 15 minutes.
[0237] 6) Wash cells with 200 μl 1X Binding Buffer.
[0238] 7) Centrifuge the cells at 1000 rpm for 2-5 min and discard the supernatant.
[0239] 8) Resuspend the cells in 190 μl of 1X Binding Buffer.
[0240] 9) Add 10 μl Propidium lodide, mix well, and react for 20 minutes in the dark.
[0241] 10) To prevent fluorescence decay, flow cytometry was performed within 4 hours.
[0242] 11) The flow cytometry results were analyzed using FlowJo_V10 software to analyze cell apoptosis.
[0243] 2.14 Statistical analysis
[0244] The experimental results were analyzed using statistical software SPSS22.0. The experimental data of quantitative data were expressed as mean ± standard deviation. If the data conformed to normal distribution and variance was equal, two independent sample t-tests were used for comparison between two groups, and one-way analysis of variance (ANOVA) was used for comparison between three or more groups. If the data did not conform to normal distribution, nonparametric rank sum test was used. p<0.05 indicated that the difference was statistically significant. GraphPad Prism 7 was used to draw the data results.
[0245] The research results of the present invention show that TJP3 is highly expressed in ovarian cancer patients and plays an important role in the proliferation, apoptosis and EMT of ovarian cancer cells, and may become a potential new biomarker for ovarian cancer.
[0246] The present invention is expected to provide new and valuable basis and reference for the diagnosis and treatment of ovarian cancer.
[0247] 1. Expression level of TJP3 in normal ovarian epithelial cells and epithelial ovarian cancer cell lines
[0248] The present invention selected 1 normal ovarian epithelial cell line, 4 epithelial ovarian cancer cell lines, and 1 fibroblastic ovarian cancer cell line for detection. The results of qRT-PCR and Western Blot showed that TJP3 was expressed to a certain extent in the normal ovarian epithelial cell line IOSE80, while the mRNA level and protein level expression in the ovarian cancer cell line were generally increased, and no obvious expression difference was observed between the epithelial ovarian cancer cell line and the fibroblastic ovarian cancer cell line. The expression level of the Caov-3 cell line was higher than that of other ovarian cancer cell lines, and its growth rate was relatively fast, so Caov-3 cells were selected as the research model for subsequent experiments.
[0249] Figure 2A to Figure 2C Schematic diagram of TJP3 mRNA and protein expression in normal ovarian epithelial and ovarian cancer cell lines; compared with IOSE-80, *p value < 0.05, **p value < 0.01, ***p value < 0.001.
[0250] 2. Construction of knockdown and overexpression stable cell lines
[0251] In order to analyze the effect of TJP3 on a series of biological functions related to the occurrence and development of tumors, such as Caov-3 cell proliferation and cell apoptosis, the present invention transferred the knockdown vectors GV248 and GV248-TJP3 and the overexpression vectors GV365 and GV365-TJP3 into Caov-3 cells, and formed two experimental groups with wild-type cells, namely, NC, Ctrl-si, TJP3-si knockdown experimental groups and NC, Ctrl-EO, TJP3-EO overexpression experimental groups.
[0252] The transfected cells were screened with puromycin selection pressure for 3 weeks, and the mRNA and protein levels were used to verify whether the obtained stable cell lines stably expressed TJP3.
[0253] The results of qRT-PCR and Western Blot showed that compared with the normal Caov-3 cell group (NC), there was no significant change in the knockdown empty control group (Ctrl-Si) and the overexpression empty control group (Ctrl-OE), indicating that the transfer of lentiviral empty vector would not affect the expression of TJP3 in cells; in contrast, the expression levels of TJP3 mRNA and protein in Caov-3 cells in the knockdown group (TJP3-Si) were significantly downregulated (p value < 0.01); the expression levels of TJP3 mRNA and protein in Caov-3 cells in the overexpression group (TJP3-OE) were significantly upregulated (p value < 0.001). The above results prove that the stable cell lines with TJP3 knockdown and overexpression were successfully constructed in Caov-3 cells.
[0254] Figure 3A to Figure 3C Schematic diagram of the expression of TJP3 mRNA and protein in the knockdown and overexpression groups of Caov-3 cell lines; compared with NC, nsp value>0.05; compared with Ctrl-Si or Ctrl-OE, **p value<0.01, ***p value<0.001.
[0255] 3. Effect of TJP3 on the proliferation activity of ovarian cancer Caov-3 cells
[0256] In order to analyze whether TJP3 has an effect on Caov-3 cell proliferation, the present invention uses the MTT method to detect cell viability. The MTT test results show that within 72 hours of the detection time, compared with the normal Caov-3 cell group (NC), the knockdown empty control group (Ctrl-Si) and the overexpression empty control group (Ctrl-OE) have almost no effect on cell proliferation activity; after knocking down TJP3 (TJP3-Si), the slope of the cell proliferation curve slows down and the proliferation rate slows down; after overexpressing TJP3 (TJP3-OE), the growth rate of Caov-3 cells accelerates. This result shows that the expression of TJP3 is positively correlated with the proliferation activity of Caov-3 cells.
[0257] Figure 4A to Figure 4B It is a schematic diagram of the in vitro proliferation ability of Caov-3 cells detected by MTT method in TJP3 knockdown and overexpression groups; compared with Ctrl-Si or Ctrl-OE, *p value < 0.05, **p value < 0.01.
[0258] 4. Effects of TJP3 on migration and invasion of ovarian cancer Caov-3 cells
[0259] The present invention adopts cell scratch test and transwell chamber invasion test respectively to analyze the effects of TJP3 knockdown and overexpression on the migration and invasion ability of Caov-3 cells.
[0260] Figure 5A to Figure 5D is a schematic diagram of the effects of TJP3 knockdown and overexpression on the migration and invasion ability of Caov-3 cells; AB are the results of cell scratch assay; CD are the results of Transwell chamber invasion assay; compared with NC, nsp value>0.05; compared with Ctrl-Si or Ctrl-OE, *p value<0.1, **p value<0.05.
[0261] The results are as follows Figure 5A , Figure 5B As shown, compared with the normal Caov-3 cell group (NC), the knockdown empty control group (Ctrl-Si) and the overexpression empty control group (Ctrl-OE) had almost no effect on the cell migration ability; TJP3 overexpression can promote cell migration, while knockdown significantly reduced the migration ability of Caov-3 cells.
[0262] The results of Transwell chamber invasion assay showed that compared with the normal Caov-3 cell group (NC), the knockdown empty control group (Ctrl-Si) and the overexpression empty control group (Ctrl-OE) had almost no effect on the invasion ability of cells; the number of Caov-3 cells penetrating the membrane after knocking down TJP3 (TJP3-Si) was significantly reduced, and compared with the Ctrl-Si group, there was a statistical difference, p value>0.05, and the number of Caov-3 cells penetrating the membrane after overexpressing TJP3 (TJP3-OE) was significantly increased. The results showed that reducing TJP3 can reduce the invasion and metastasis ability of cells, while high expression can promote the invasion and metastasis ability of cells.
[0263] 5. Effect of TJP3 on the expression of EMT-related proteins in ovarian cancer Caov-3 cells
[0264] Epithelial-mesenchymal transition (EMT) is an important process during development, during which epithelial cells acquire mesenchymal fibroblast-like properties, showing reduced intracellular adhesion and increased motility. This is a key feature of normal embryonic development, which is exploited by malignant epithelial tumors for tumor spread. This tightly regulated process is associated with a large number of cellular and molecular events. EMT depends on the reduction of expression of cell adhesion molecules.
[0265] Cadherins mediate calcium-dependent cell-cell adhesion and play a key role in normal tissue development. E-cadherin is considered to be an active inhibitor of invasion and growth in many epithelial cancer cells. Recent studies have shown that in addition to the loss of E-cadherin, cancer cells also have upregulated N-cadherin expression. This change in cadherin expression is called the "cadherin switch," with downregulation of E-cadherin expression and upregulation of N-cadherin.
[0266] Upregulated expression is a set of hallmarks of EMT. Snail is a zinc finger transcription factor that inhibits epithelial E-cadherin transcription. In epithelial tumor cell lines, the mRNA levels of Snail and E-cadherin are negatively correlated to a large extent. Vimentin is the main type of cytoskeletal intermediate filaments. The structural rearrangement of vimentin filaments during EMT is very important during cell adhesion and cell migration.
[0267] Western Blot results showed that compared with the normal Caov-3 cell group (NC), the intracellular proteins in the knockdown empty control group (Ctrl-Si) and the overexpression empty control group (Ctrl-OE) did not change much; compared with the overexpression empty control group (Ctrl-OE), the expression levels of Snail, N-cadherin, and Vimentin in Caov-3 cells increased after overexpression of TJP3 (TJP3-OE), and the expression of E-cadherin protein decreased. The trend was opposite after knockdown of TJP3 (TJP3-Si), and the expression levels of Snail, N-cadherin, and Vimentin decreased to varying degrees, while the expression of E-cadherin protein increased; the expression trend of EMT-related proteins was consistent with previous reports, indicating that under the conditions of the Caov-3 cell model, the increased expression of TJP3 inhibited the expression of E-cadherin in cells, while promoting the expression of Snail, N-cadherin, and Vimentin, thereby enhancing the invasion and migration ability of Caov-3 cells.
[0268] Figure 6A to Figure 6BSchematic diagram of the effects of TJP3 knockdown and overexpression on the expression of EMT-related proteins in Caov-3 cells; compared with Ctrl-Si or Ctrl-OE, *p value < 0.05, **p value < 0.01.
[0269] 6. Effect of TJP3 on apoptosis of ovarian cancer Caov-3 cells
[0270] Annexin V-FITC / PI double staining cell apoptosis detection method was used to detect the effect of TJP3 on cell apoptosis. The two-dimensional scatter plot of flow cytometry showed that compared with the normal Caov-3 cell group (NC), the distribution of cells in the knockdown empty control group (Ctrl-Si) and the overexpression empty control group (Ctrl-OE) in the four quadrants was roughly the same, and the apoptosis percentage was between 6.45% and 6.7%, with no statistically significant difference p value>0.05; after knocking down TJP3 (TJP3-Si), the number of necrotic cells in the Q1 zone, late apoptotic cells in the Q2 zone, and early apoptotic cells in the Q3 zone of Caov-3 cells increased. Compared with the Ctrl-Si group, the cell apoptosis rate increased by 80.8%, with a significant difference p value <0.01, and the apoptosis of cells in the TJP3-OE group decreased by 44%, p value <0.01. The experimental results show that TJP3 reduction can promote Caov-3 cell apoptosis, while high expression can inhibit Caov-3 cell apoptosis.
[0271] Figure 7A to Figure 7B This is a schematic diagram of the effect of TJP3 on Caov-3 cell apoptosis detected by Annexin V-FITC / PI double staining; compared with NC, nsp value>0.05; compared with Ctrl-Si or Ctrl-OE, *p value<0.05, **p value<0.01.
[0272] The above series of experimental results clearly show that high expression of TJP3 promotes the proliferation activity, cell migration, cell invasion, and inhibits cell apoptosis of ovarian cancer cells, indicating that TJP3 has a clear biological function in the occurrence and development of ovarian cancer cells.
[0273] So far, there are few literature reports on TJP3 in the field of gynecological tumors, and no reports related to ovarian cancer. The research team verified its role in the occurrence and development of ovarian cancer through research, which may lay a good foundation for further in-depth exploration of TJP3 in the clinical diagnosis, classification, treatment, and prognosis of ovarian cancer.
[0274] The existing tumor markers reflect many limitations in their application, for example, some normal cells also produce tumor markers, and diseases other than cancer or stress states may also significantly increase the levels of tumor markers; the serum levels of tumor markers are not stable and may change over time, making it difficult to obtain consistent results; some tumors do not produce tumor markers that can be detected in the blood. The next-generation sequencing technology provides new technical means for studying gene function and also provides reliable clues for finding candidate target molecules and biomarkers for tumors. The TJP3 functional study covers the detection data of clinical tissue samples and the verification of in vitro cell levels. The experimental data is reliable and the result analysis is reasonable.
[0275] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention. <110> Kunming Medical University <120> Application of a TJP3 gene encoding protein in the preparation of ovarian cancer detection reagent <160> 6 <210> 1 <211> 19 <212> DNA <213> Artificial Sequence <400> 1 ggtgaacattcctcgagga <210> 2 <211> 18 <212> DNA <213> Artificial Sequence <400> 2 gcagaagttctcgagaac <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <400> 3 gctactcgagtagcttccct <210> 4 <211> 19 <212> DNA <213> Artificial Sequence <400> 4 ttctccgaacgtgtcacgt <210> 5 <211> 40 <212> DNA <213> Artificial Sequence <400> 5 aaactggcttctcgcaacac ccttctacatccgcactcac <210> 6 <211> 38 <212> DNA <213> Artificial Sequence <400> 6 gacctgacctgccgtctag gacctgacctgccgtctag
Claims
1. A method for determining the function of an encoded protein, It is characterized in that The method for determining the function of the encoded protein comprises: Step 1, detecting the expression levels of mRNA and protein of TJP3 protein in normal ovarian epithelial cells and epithelial ovarian cancer cell lines; Step 2: Construction of knockdown and overexpression stable cell lines; Step 3, detecting the effect of TJP3 protein on the proliferation activity of ovarian cancer Caov-3 cells; Step 4, detecting the effect of TJP3 protein on the migration and invasion of ovarian cancer Caov-3 cells; Step 5, detecting the expression of EMT-related proteins in ovarian cancer Caov-3 cells by TJP3 protein; Step six, detecting the effect of TJP3 protein on apoptosis of ovarian cancer Caov-3 cells; The method for constructing knockdown and overexpression stable cell lines in step 2 comprises: The knockdown vectors GV248, GV248-TJP3 and the overexpression vectors GV365, GV365-TJP3 were transferred into Caov-3 cells, and formed two experimental groups with wild-type cells respectively; the transfected cells were screened with puromycin selection pressure for 3 weeks, and the mRNA level and protein level were used to verify whether the obtained stable cell lines stably expressed TJP3 protein, and then used to analyze the effects of TJP3 protein on the proliferation activity of ovarian cancer Caov-3 cells, the effects on the migration and invasion of ovarian cancer Caov-3 cells, the expression of EMT-related proteins in ovarian cancer Caov-3 cells, and the effect on the apoptosis of ovarian cancer Caov-3 cells.
2. The method for determining the function of the encoded protein according to claim 1, It is characterized in that The method for detecting the expression level of mRNA and protein of TJP3 protein in normal ovarian epithelial cells and epithelial ovarian cancer cell lines in step 1 comprises: One normal ovarian epithelial cell line, four epithelial ovarian cancer cell lines and one fibroblastic ovarian cancer cell line were selected to detect the expression level of TJP3 protein.
3. The method for determining the function of the encoded protein according to claim 1, It is characterized in that The method for detecting the effect of TJP3 protein on the migration and invasion of ovarian cancer Caov-3 cells in step 4 includes: using cell scratch assay and transwell chamber invasion assay to analyze the effect of TJP3 protein knockdown and overexpression on the migration and invasion ability of Caov-3 cells.
4. The method for determining the function of the encoded protein according to claim 3, It is characterized in that The experimental groups include NC, Ctrl-si, TJP3-si knockdown experimental groups and NC, Ctrl-EO, TJP3-EO overexpression experimental groups.
5. The method for determining the function of the encoded protein according to claim 1, It is characterized in that The method for detecting the effect of TJP3 protein on the proliferation activity of ovarian cancer Caov-3 cells in step three includes: using MTT method to detect cell activity and analyzing whether TJP3 protein has an effect on the proliferation of Caov-3 cells.
6. The method for determining the function of the encoded protein according to claim 1, It is characterized in that The method for detecting the effect of TJP3 protein on the expression of EMT-related proteins in ovarian cancer Caov-3 cells in step 5 includes: using Western Blot to detect the effect of TJP3 protein on the expression of EMT-related proteins in ovarian cancer Caov-3 cells.
7. The method for determining the function of the encoded protein according to claim 1, It is characterized in that The method for detecting the effect of TJP3 protein on apoptosis of ovarian cancer Caov-3 cells in step six includes: using Annexin V-FITC / PI double staining cell apoptosis detection method to detect the effect of TJP3 protein on cell apoptosis.
